The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
FRI06 - Industry Sponsored Session | Advances in targeted therapy for CLL and AML: Efficacy and practical management of BCL-2 inhibitors Presented by AbbVie
This session will provide advanced practitioners an understanding of venetoclax safety and efficacy data. In addition, the practical management of venetoclax therapy in patients with CLL and AML will be discussed.
